ClinicalTrials.gg
WithdrawnNCT03508453Updated May 5, 2026

IC14 for Treatment of Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of IC14 and Placebo in Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by Implicit Bioscience. Withdrawn at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Implicit Bioscience · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
No participants enrolled in study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.

Enrollment
42nd of 44
0 · median 63
Started
2021
with 9 others
Phase 2
17 of 44
2 open now
Registered
11th of 44
by date
Lead sponsor
3 of 44
Implicit Bioscience

Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 42nd largest by enrollment, is one of 10 that started in 2021, is one of 17 in phase 2, and was the 11th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, or all of them as a file.
02

Study summary

Fifty patients with amyotrophic lateral sclerosis that is progressing rapidly will be randomized to receive either the monoclonal antibody IC14 or placebo to be given intravenously over two hours twice weekly for 12 weeks. Blood and urine tests will be done to measure biomarkers in order to evaluate clinical response and to monitor for safety. Other evaluations include patient questionnaires about function, quality of life and mental function; pulmonary function test; and sniff nasal pressure.

Read the detailed description

This will be a placebo-controlled, double-blind, parallel-group comparison.

Fifty patients with rapidly progressive ALS will be randomised to receive one of the following regimens:

  • IC14 4 mg/kg given intravenously twice weekly for 12 weeks; or
  • Identical-appearing placebo given intravenously twice weekly for 12 weeks. There will be an interim safety review by an independent Data Safety Monitoring Board after the initial 20 subjects have completed 4 weeks and 8 weeks of treatment. Study observation will continue until 12 weeks after the last dose of study drug.

The primary endpoint is:

  • Treatment-related change in disease biomarker profiles [e.g., neurofilaments (Nf), urinary p75 neurotrophin receptor (p75NTR), cytokines, and soluble CD14].

The secondary endpoints are:

  • Safety, tolerability and lack of immunogenicity of IC14.
  • Treatment-related change in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).
  • Treatment-related change in respiratory function by seated forced vital capacity (FVC) parameters.
  • Treatment-related change in inspiratory muscle strength by sniff nasal pressure (SNP) test.
  • Treatment-related change in quality of life by the ALS Specific Quality of Life-Revised (ALSSQOL-R) score.
  • Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioural Assessment (ECAS) score.
  • Treatment-related changes stratified by disease severity and prognostic indicators.
  • Peak serum IC14 concentration following administration of the initial dose and peak serum concentration following a course of treatment.
  • Area under the serum IC14 concentration versus time curve (AUC) following administration of the initial dose and following a course of treatment.
03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease

Keywords

  • monoclonal antibody
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to initiation of any study-specific procedures.
  2. Familial or sporadic MND defined as clinically possible, probable, or definite by Awaji-Shima Consensus Recommendations.
  3. Rapidly progressive MND as defined by a decline of 3 or more points in the ALSFRS-R score during the prior 3 months.
  4. First symptoms of MND within 3 years of informed consent.
  5. Age between 18 and 75 years at time of informed consent.
  6. Seated Forced Vital Capacity (FVC) ≥ 65% of predicted value.
  7. Not taking riluzole or edaravone or on a stable dose of riluzole or edaravone for at least 3 months prior to screening visit.
  8. Adequate bone marrow reserve, renal and liver function:

    • ≥ 1.5 x 109/L
    • lymphocyte count \< 6.0 x 109/L
    • count ≥ 150 x 109/L
    • ≥ 110 g/L
    • ≥ 40 mL/min/1.73 m2
    • and/or AST ≤ 2x
    • total ≤ 1.5x ULN
    • serum albumin ≥ 28 g/L
  9. Females of should be using and committed to continue using one of the following acceptable methods:

    • Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
    • Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
    • Stable hormonal contraception for at least 3 months prior to study through study completion; or
    • Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
  10. To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be and at least 3 years since last menses.
  11. Males with female partners of childbearing potential must use contraception through study completion.
  12. Able to give informed consent and able to comply with all study visits and all study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Dependence on mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at screening; or presence of diaphragm pacing system at screening.
  2. Treatment with a drug or device within the last 30 days that has not received regulatory approval.
  3. Treatment within 12 months with immunomodulator or agent (including but not limited to cyclophosphamide, cyclosporine, interferon-α, interferon-β-1a, rituximab, alemtuzumab, azathioprine, etanercept, infliximab, adalimumab, certolizumab, golimumab, anakinra, rilonacept, secukinumab, tocilizumab, mycophenolate mofetil, methotrexate, haematopoietic stem cell transplantation, anti-sense drugs, gene therapy, cell-depleting agents, total lymphoid irradiation). Treatment with intravenous immunoglobulin within 2 months or dimethyl fumarate within 3 months. Non-steroidal anti-inflammatory drugs are acceptable.
  4. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other opportunistic infections; or major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks.
  5. within 30 days before dosing. Subjects must agree to forego live-attenuated vaccines throughout the study, including 12 weeks after the last dose of study drug.
  6. History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.
  7. Presence of any of the following clinical conditions:

    • History of one or more of the following: cardiac insufficiency ( [NYHA] III/IV), uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg).
    • History of venous thromboembolic disease within 12 months, myocardial infarction, or cerebrovascular accident.
    • Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.
    • disease, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis.
    • Evidence of active malignant disease, diagnosed within the previous 5 years, or breast cancer diagnosed within the previous 5 years (except skin cancers other than melanoma).
    • History of infection or other immunodeficiency illness.
    • Unstable psychiatric illness defined as psychosis or untreated major depression within 90 days.
    • History of drug abuse (not including marijuana use) or alcoholism within the past 12 months.
    • Significant neuromuscular disease other than MND.
    • Other ongoing disease that may cause neuropathy, such as toxin exposure, dietary deficiency, uncontrolled diabetes, hyperthyroidism, cancer, systemic lupus erythematosus or other connective diseases, infection with HIV, virus (HBV), or (HCV), Lyme disease, multiple myeloma, Waldenström's macroglobulinemia, amyloid, and hereditary neuropathy.
  8. Pregnancy or breastfeeding.
  9. Deprivation of freedom by administrative or court order.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    IC14 (monoclonal anti-CD14 antibody)

    IC14 4 mg/kg intravenously twice weekly for 12 weeks

    Biological: IC14

  • Placebo comparator
    Placebo

    Placebo intravenously twice weekly for 12 weeks

    Other: Placebo

Interventions

  • BiologicalAtibuclimabStudies of AtibuclimabAtibuclimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Monoclonal antibody against CD14

  • OtherPlacebo

    sterile normal saline for injection prepared to be identical to study drug

06

What researchers measure

Primary outcomes

  1. Neurofilament (biomarker)

    Treatment-related change in concentration of neurofilament (picograms per milliliter)

    Time frame: 12 weeks

  2. Urinary p75 neurotrophin receptor (biomarker)

    Treatment-related change in concentration of urinary p75 neurotrophin receptor (nanograms per milligram creatinine)

    Time frame: 12 weeks

  3. Monocyte CD14 receptor occupancy

    Treatment-related change in percent monocyte receptor occupancy

    Time frame: 12 weeks

Secondary outcomes

  1. Functional status

    Treatment-related change in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale \[0 (worst) to 48 (best)\]

    Time frame: 12 weeks

  2. Respiratory function

    Treatment-related change in percent normal Forced Vital Capacity \[0% (worst) to 100%(best)\]

    Time frame: 12 weeks

  3. Muscle function

    Treatment-related change in percent normal Sniff Nasal Pressure \[0% (worst) to 100% (best)\]

    Time frame: 12 weeks

  4. Quality of life measured by ALSSQOL

    Treatment-related change in Amyotrophic Lateral Sclerosis Specific Quality of Life - Revised questionnaire \[0 (worst) to 460 (best)\]

    Time frame: 12 weeks

  5. Cognitive and behavioural assessment

    Treatment-related change in Edinburgh Cognitive and Behavioural Assessment Score \[0(worst) to 136 (best)\]

    Time frame: 12 weeks

  6. Maximum plasma concentration (Cmax)

    Maximum serum IC14 concentration (micrograms per milliliter)

    Time frame: 12 weeks

  7. Area under the curve

    Area under the curve for serum IC14 (microgram x hr/mL)

    Time frame: 12 weeks

  8. Immunogenicity

    Development of human anti-monoclonal antibodies following treatment

    Time frame: 16 weeks

  9. Adverse events (safety, tolerability)

    Incidence of treatment-emergent adverse events (safety, tolerability) classified by MedDRA

    Time frame: 16 weeks

07

Study locations

1 site
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4006, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2021; primary completion for May 2023, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2018
First posted
Apr 25, 2018
StartEst.
Aug 15, 2021
Primary completionEst.
May 15, 2023
CompletionEst.
Dec 15, 2023
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03508453
Lead sponsor
Implicit Bioscience
Responsible party
Sponsor
First posted
Apr 25, 2018
Start date
Aug 15, 2021 (estimated)
Primary completion
May 15, 2023 (estimated)
Completion
Dec 15, 2023 (estimated)
Last update
May 5, 2026

Study contacts

Robert D Henderson, MBBS
study chair · Royal Brisbane & Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atibuclimab

Start the discussion